Derivatives Reform May Not Mean Greater OTC Transparency
New derivatives regulation aimed at making the market more transparent may not accomplish its goal, according to Craig Donohue, ceo of CME Group.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
